Filtered By:
Condition: Atrial Fibrillation
Nutrition: Sodium

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 85 results found since Jan 2013.

Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis
Globally, the number of people estimated to have diabetes mellitus (DM) in 2019 was 463 million, and the estimated number is expected to rise to 578 million people by 2030.1 DM is also associated with an increased risk of atrial fibrillation (AF), 2 and has shown to be an independent risk factor for stroke in patients with AF.3 A meta-analysis of 102 studies further showed that patients with diabetes have a higher risk of all subtypes of stroke (ischemic, hemorrhagic and unclassified stroke).4 This has generated great interest in anti-hyperglycemic agents and their ability to reduce the cardiovascular complications of diabetes.
Source: Journal of Stroke and Cerebrovascular Diseases - October 22, 2021 Category: Neurology Authors: How Ting Ong, Yao Hao Teo, Yao Neng Teo, Nicholas LX Syn, Caitlin Fern Wee, Shariel Leong, Alicia Swee Yan Yip, Ray Meng See, Adriel Zhi Hen Ting, Alys ZQ Chia, Alex Jia Yang Cheong, Benjamin Yong-Qiang Tan, Jamie Sin-Ying Ho, Leonard Leong-Litt Yeo, Aloy Source Type: research

Determinants of Use of Long-term Continuous Electrocardiographic Monitoring for Acute Ischemic Stroke Patients without Atrial Fibrillation at Baseline.
CONCLUSIONS: When selecting the high-risk group of patients (with an NIHSS score > 12 and age > 64.5 years, or with an NIHSS score ≤ 12, age > 71.5 years, and triglyceride level ≤ 61.5 mg/dL) according to the CART model, the detection rate of paroxysmal AF was approximately double in the acute ischemic stroke patients without AF at baseline. PMID: 32324514 [PubMed - as supplied by publisher]
Source: Current Neurovascular Research - April 21, 2020 Category: Neurology Authors: Lee JD, Huang YC, Lee M, Lee TH, Kuo YW, Hu YH, Ovbiagele B Tags: Curr Neurovasc Res Source Type: research

Predicting 10-year stroke mortality: development and validation of a nomogram
AbstractPredicting long-term stroke mortality is a clinically important and unmet need. We aimed to develop and internally validate a 10-year ischaemic stroke mortality prediction score. In this UK cohort study, 10,366 patients with first-ever ischaemic stroke between January 2003 and December 2016 were followed up for a median (interquartile range) of 5.47 (2.96 –9.15) years. A Cox proportional-hazards model was used to predict 10-year post-admission mortality. The predictors associated with 10-year mortality included age, sex, Oxfordshire Community Stroke Project classification, estimated glomerular filtration rate (eG...
Source: Acta Neurologica Belgica - August 18, 2021 Category: Neurology Source Type: research

Development of Quality Indicators of Stroke Centers and Feasibility of Their Measurement Using a Nationwide Insurance Claims Database in Japan 　- J-ASPECT Study.
CONCLUSIONS: We developed QIs for primary and comprehensive stroke care. The DPC database may allow efficient data collection at low cost and decreased burden to evaluate the developed QIs. PMID: 31554766 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 25, 2019 Category: Cardiology Authors: Nishimura A, Nishimura K, Onozuka D, Matsuo R, Kada A, Kamitani S, Higashi T, Ogasawara K, Shimodozono M, Harada M, Hashimoto Y, Hirano T, Hoshino H, Itabashi R, Itoh Y, Iwama T, Kohriyama T, Matsumaru Y, Osato T, Sasaki M, Shiokawa Y, Shimizu H, Takekawa Tags: Circ J Source Type: research

Role of IL-17A in different stages of ischemic stroke
Int Immunopharmacol. 2023 Apr;117:109926. doi: 10.1016/j.intimp.2023.109926. Epub 2023 Mar 11.ABSTRACTInterleukin-17A (IL-17A) plays an important role in the progression of ischemic stroke. IL-17A mediates the endothelial inflammatory response, promotes water and sodium retention, and changes the electrophysiological structure of the atrium, accelerating the progression of ischemic stroke risk factors such as atherosclerotic plaques, hypertension, and atrial fibrillation. In the acute phase of ischemic stroke, IL-17A mediates neuronal injury through neutrophil chemotaxis to the site of injury, the induction of neuronal apo...
Source: International Immunopharmacology - April 4, 2023 Category: Allergy & Immunology Authors: Xiuping Chen Yi Zhang Qian Ding Yanru He Hui Li Source Type: research

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
ConclusionsBased on real-world data of type 2 diabetic patients in Hong Kong, SGLT2I use was associated with lower risk of incident AF, stroke/transient ischemic attack, and cardiovascular and all-cause mortality outcomes compared to DPP4I use.
Source: Cardiovascular Drugs and Therapy - February 10, 2022 Category: Cardiology Source Type: research

Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Diabetes Metab. 2023 Sep 5:101474. doi: 10.1016/j.diabet.2023.101474. Online ahead of print.ABSTRACTStroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal disease. Some data suggested that glucagon peptide-1 receptor agonists (GLP-1RAs) exert a better protection against stroke than sodium-glucose cotransporter 2 inhibitors (SGLT2is). However, this conclusion was derived from indirect comparisons in absence of any head-to-head randomised controlled trial (RCT). The present...
Source: Diabetes and Metabolism - September 7, 2023 Category: Endocrinology Authors: Andr é J Scheen Source Type: research

Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented effects on reducing hospitalization for heart failure and cardiovascular mortality, although the effect on atrial fibrillation (AF) has not been comprehensively investigated. Therefore, we performed a meta-analysis to assess the association between SGLT2 inhibitors and AF risk by systematically searching PubMed, Embase, and ClinicalTrials.gov. Two investigators independently identified randomized controlled trials, which compared SGLT2 inhibitors with control in patients with type 2 diabetes, heart failure, or chronic kidney disease. Prima...
Source: Journal of Cardiovascular Pharmacology - February 1, 2022 Category: Cardiology Tags: Review Article Source Type: research

Anticoagulation Timing for Atrial Fibrillation in Acute Ischemic Stroke
Most stroke physicians will have been asked the best time to start anticoagulation for a patient with atrial fibrillation (AF) and acute ischemic stroke. There is no question that long-term anticoagulation with a direct oral anticoagulant or warfarin sodium reduces the risk of strokes in patients with AF, but the right time to start anticoagulation is uncertain.
Source: JAMA Neurology - September 11, 2017 Category: Neurology Source Type: research

Rivaroxaban vs Warfarin Sodium Early After AF-Related Mild Ischemic Stroke
This randomized clinical trial examines whether rivaroxaban or warfarin sodium is safer and more effective for preventing early recurrent stroke in patients with atrial fibrillation –related acute ischemic stroke.
Source: JAMA Neurology - September 11, 2017 Category: Neurology Source Type: research

Anticoagulation Timing for Atrial Fibrillation in Acute Ischemic Stroke
Most stroke physicians will have been asked the best time to start anticoagulation for a patient with atrial fibrillation (AF) and acute ischemic stroke. There is no question that long-term anticoagulation with a direct oral anticoagulant or warfarin sodium reduces the risk of strokes in patients with AF, but the right time to start anticoagulation is uncertain.
Source: JAMA Neurology - October 1, 2017 Category: Neurology Source Type: research